MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on July 30, 2004; DOI: 10.1124/mol.104.002774


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.104.002774v1
66/5/1103    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Visan, V. M.
Right arrow Articles by Grissmer, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Visan, V. M.
Right arrow Articles by Grissmer, S.


Received for publication May 17, 2004.
Revised June 22, 2004.
Accepted for publication July 27, 2004.

Mapping of maurotoxin binding sites on hKv1.2, hkv1.3 and hIKCa1 channels

Violeta Monica Visan 1, Ziad Fajloun 2, Jean-Marc Sabatier 2, Stephan Grissmer 1*

1 University of Ulm 2 Laboratoire International Associe d'Ingenierie Biomoleculaire, Marseille

* Address correspondence to: E-mail: stephan.grissmer{at}medizin.uni-ulm.de

Abstract

Maurotoxin (MTX) is a potent blocker of human voltage-activated Kv1.2 and intermediate-conductance calcium-activated potassium channels, hIKCa1. Since its blocking affinity on both channels is similar, although the pore region of these channels show only few conserved amino acids, we aimed to characterize the binding sites of MTX in these channels. Investigating the pHo dependency of MTX block on current through hKv1.2 channels, we concluded that the block is less pHo sensitive than for hIKCa1 channels. Using mutant cycle analysis and computer docking we tried to identify the amino acids through which MTX binds to hKv1.2 and hIKCa1 channels. We report that MTX interacts with hKv1.2 mainly though six strong interactions. Lys23 from MTX protrudes into the channel pore interacting with the GYGD motif, while Tyr32 and Lys7 interact with Val381, Asp363, and Glu355, stabilising the toxin onto the channel pore. Since only Val381, Asp363, and the GYGD motif are conserved in hIKCa1 channels, and the replacement of His399 from hKv1.3 channels with a threonine makes this channel MTX sensitive, we concluded that MTX binds to all three channels through the same amino acids, Glu355, although important, being not essential in MTX recognition. A negatively charged amino acid in this position could better stabilize the toxin-channel interaction, and could explain the pHo sensitivity of MTX block on current through hIKCa1 versus hKv1.2 channels.


Key words: Structure-activity relationships and modeling, Func. analysis receptor/ion channel mutants, Mutagenesis/Chimeric approaches, Structure/function/mechanism


This article has been cited by other articles:


Home page
Biophys. JHome page
J. Nilsson, M. Madeja, F. Elinder, and P. Arhem
Bupivacaine Blocks N-Type Inactivating Kv Channels in the Open State: No Allosteric Effect on Inactivation Kinetics
Biophys. J., December 1, 2008; 95(11): 5138 - 5152.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
B. Gilquin, S. Braud, M. A. L. Eriksson, B. Roux, T. D. Bailey, B. T. Priest, M. L. Garcia, A. Menez, and S. Gasparini
A Variable Residue in the Pore of Kv1 Channels Is Critical for the High Affinity of Blockers from Sea Anemones and Scorpions
J. Biol. Chem., July 22, 2005; 280(29): 27093 - 27102.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
M. Bagdaany, C. V. F. Batista, N. A. Valdez-Cruz, S. Somodi, R. C. R. de la Vega, A. F. Licea, Z. Varga, R. Gaspar, L. D. Possani, and G. Panyi
Anuroctoxin, a New Scorpion Toxin of the {alpha}-KTx 6 Subfamily, Is Highly Selective for Kv1.3 over IKCa1 Ion Channels of Human T Lymphocytes
Mol. Pharmacol., April 1, 2005; 67(4): 1034 - 1044.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics